Thermo Fisher Scientific (TMO)
Salud / Herramientas de ciencias de la vida
The most comprehensive laboratory and outsourced pharmaceutical services provider, with a stable and broad moat, trades at 29× on adjusted operating income after taxes while revenue grows at a mid-single-digit rate: Overvalued, with an estimated return of -0% annually because the multiple compression to 23× absorbs nearly all of the growth.
- Price
- $628.66
- Intrinsic value (5y, base)
- $602
- Total annual return (5y)
- -0.5%
- Status (nominal)
- Overvalued
- Margin of safety
- No margin
The essentials
- Four segments covering the full spectrum of life sciences—reagents, instruments, diagnostics, and pharmaceutical manufacturing—backed by a direct sales force of approximately 14,000 representatives and leading brands (Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Patheon, PPD).
- Revenue recovered from the post-pandemic decline: −4.6% in 2023, +0.1% in 2024, +3.9% in 2025, and +5.4% in the TTM, though organic growth in 2025 was +2% (one point from acquisitions and another from currency conversion).
- Return on invested capital stands at 10% versus the 10% bar, a result of three decades of acquisitions: invested capital carries $49,360 million in goodwill and $15,830 million in intangibles, not a mediocre operation.
Intrinsic value — two valuation methods
Total return at 5 years: -0.5%/year = -0.9% appreciation + 0.4% dividend. The target price ($602) is ex-dividend; the $12 in dividends collected over 5 years are added separately.
By both methods, the value today (DCF $570 · Multiples $494) is below the market price ($629).
Pillars of the analysis
The verdict — today vs 5 years
Today — expensive, no margin of safety: at $629 trades ~27.3% above its value discounted to today (~$494); the expected return does not even reach the risk-free rate (4.5%).
At 5 years — Sobrevalorado: the expected total return is negative — the price already discounts a demanding scenario that, if not met, results in a loss.
The bridge: the return at 5 years falls below the risk-free rate (4.5%) — which is why there is not even a discount to today's value. To require a 15% annual return, it would need to be bought at ~$307.
Thesis
The business
It is a high-quality franchise: recurring revenue from consumables and services, regulatory switching costs, unmatched industry scale, and an adjusted operating margin of 22.7% sustained through the post-pandemic contraction in scientific spending. Return on invested capital of 9.9% falls below the 10% bar, but the denominator carries the price paid in three decades of acquisitions ($49,360 million in goodwill), not slack operations.
The valuation
Valued at a single multiple on adjusted operating income after taxes, the measure the company reconciles in the 10-K that excludes amortization of intangibles from acquisitions. The base case projects revenue growing from 4.5% to 4.1% annually, adjusted operating margin rising from 22.7% to 24.0% with declared restructuring savings, and an exit multiple of 20.5×, within the archetype band. The result is $602 per share at five years against $629 at current prices.
The margin of safety
No margin of safety: the price already discounts a demanding scenario. The estimated total return is -0% annually: the business compounds, but the entry multiple of 29× compresses to 23× and absorbs nearly all of what growth contributes. The dividend yield, 0.3%, does not change the picture. The verdict is Overvalued: quality is not in question, price leaves no cushion.
What to watch
The disconfirmer is organic growth: if revenue organic growth does not clearly exceed the +2% of 2025 and the path sustains itself only on acquisitions, the current multiple loses its justification and compression accelerates. On the other hand, a recovery in pharmaceutical industry spending and public research budgets would return mid-to-high single-digit organic growth and justify the high end of the band.
Educational / informational. Does not constitute investment advice.